References: John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Thomas A Wadden, Sean Wharton, Koutaro Yokote, Niels Zeuthen, Robert F Kushner
One subsequent analysis has estimated that 7.9 million individuals meet the SELECT trial criteria in the US: Among these individuals, treatment with semaglutide could prevent about 190 000 cardiovascular events in 5 years. If each eligible patient received semaglutide at a retail price of $16 188 per year, the total cost would amount to $127 billion per year. The authors of SELECT noted that: Potentially less costly alternatives for reducing obesity and CVD risk include lifestyle counseling, dietary fasting, and alternative pharmacological weight loss approaches
Keep a symptom log
Stay hydrated, avoid strenuous activity for a few hours, and follow your personalised booster schedule as recommended